This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.
Gain insight into research trends and influential papers with Research Intelligence.
doi.org/10.1056/nejmoa2107519
Original paper

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

..., Katelyn Brown
10
New England Journal of Medicine96.20
Volume: 385, Issue: 6, Pages: 503 - 515
Published: Jun 25, 2021
Abstract
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes. The efficacy and safety of once-weekly tirzepatide as compared with semaglutide, a selective GLP-1 receptor agonist, are...
Paper Fields
Paper Details
Title
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
DOI
doi.org/10.1056/nejmoa2107519
Published Date
Jun 25, 2021
Journal
New England Journal of Medicine
Volume
385
Issue
6
Pages
503 - 515
© 2025 Pluto Labs All rights reserved.
Step 1. Scroll down for details & analytics related to the paper.
Discover a range of citation analytics, paper references, a list of cited papers, and more.